Ireland-headquartered biotech firm Alkermes (Nasdaq: ALKS) on Tuesday said the US Food and Drug Administration has approved its drug to treat schizophrenia and that it is looking to immediately launch the product.
Alkermes expects to price the product at $1,500 per script, in line with other available treatments in the class, the company said in a conference call.
Aristada (aripiprazole lauroxil) is the first atypical antipsychotic injection, which will be available as a once-monthly and six-week dosing options the company said in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze